Restores melatonin secretion and normalizes sleep cycles, especially in individuals over 50
However, microdosing is considered an off-label practice with limited clinical research, and professional organizations including the American Diabetes Association do not formally endorse it
Initially approved for treatment of Type 2 diabetes and later for obesity studies in GLP-1 are now expanding in other indications such as obstructive sleep apnea (OSA), heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD)
John: You know, Nayan, we were talking before we started taping this
Understanding the available pathways helps inform decisions about whether and how to proceed
Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al., 2023)